Vimarsana
Biggest News Aggregation in the World

Page 3 - Colitis Organization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Colitis Organization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Colitis Organization Today - Breaking & Trending Today

FDA Issues Response Letter for Mirikizumab - Vimarsana News

FDA Issues Response Letter for Mirikizumab

The FDA cited manufacturing concerns in their letter for the potential ulcerative colitis treatment.

New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis - Vimarsana News

New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab)...

TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies - Vimarsana News

TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to...

Cannabis Tied to Lower IBD Mortality, Hospital Costs - Vimarsana News

Cannabis Tied to Lower IBD Mortality, Hospital Costs

Patients with IBD who concurrently use cannabis show a highly significant reduction in inpatient mortality and hospital length of stay and around 25% drop in hospitalization costs.

Galapagos NV: Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023 - Vimarsana News

Galapagos NV: Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib